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Impaired polyfunctionality of CD8+ T cells in severe
sepsis patients with human cytomegalovirus
reactivation
Young Joon Choi1,5, Sun Bean Kim2,5, Jong Hoon Kim1, Su-Hyung Park3, Moo Suk Park4, June Myung Kim2,
Sang Hoon Han2 and Eui-Cheol Shin1
Human cytomegalovirus (HCMV) establishes a lifelong chronic latent infection and often reactivates in immunocompromised
patients. In addition, HCMV reactivates in patients with sepsis or other critical illnesses, particularly in patients with poor prognoses.
However, the immunological characteristics of sepsis patients with HCMV reactivation have not been elucidated. In the present
study, we examined T-cell responses in severe sepsis patients with and without HCMV reactivation. First, HCMV pp65-speciﬁc T-cell
functions were assessed by intracellular cytokine staining (ICS) for IFN-γ, TNF-α, and MIP-1β and by CD107a staining. We analyzed
the ICS data for each function individually and found no difference between the patient groups. However, the relative frequency of
polyfunctional CD8+ T cells was signiﬁcantly decreased in sepsis patients with HCMV reactivation. Next, we examined programmed
cell death protein 1 (PD-1) expression. It was signiﬁcantly increased in the CD8+ T-cell population in severe sepsis patients with
HCMV reactivation, indicating CD8+ T-cell exhaustion. Interestingly, the frequency of PD-1+ cells in the CD8+ T-cell population was
inversely correlated with the relative frequency of polyfunctional CD8+ T cells. Herein, we demonstrate that HCMV reactivation in
severe sepsis patients is associated with PD-1 expression and impaired polyfunctionality of CD8+ T cells.
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INTRODUCTION
Human cytomegalovirus (HCMV) is a member of the
β-herpesvirus family and is widely recognized as a common
opportunistic pathogen of immunocompromised hosts, such as
solid organ transplantation recipients, patients with hematolo-
gic malignant disorders and human immunodeﬁciency virus-1-
infected individuals.1–3 Primary HCMV infection is usually
asymptomatic, but HCMV establishes lifelong latency similar
to other herpesviruses. HCMV often reactivates in immuno-
compromised hosts, and the lytic reactivation of HCMV is
known to worsen the clinical outcomes of various diseases that
result in immunosuppression.4,5
HCMV reactivation has also been studied in patients with
sepsis or other critical illnesses without predisposing
immunocompromised conditions. HCMV often reactivates in
critically ill patients and is correlated with increased mortality
and morbidity (that is, longer hospital stays and frequent or
longer mechanical ventilation).6–15 HCMV reactivation is
thought to be caused by excessive inﬂammatory cytokine
release, epigenetic alterations of viral DNA and immune
suppression.16–19 HCMV reactivation has been suggested to
indicate critical illness-induced immunosuppression, which
worsens the clinical outcomes by itself.11 In addition, it has
been suggested that HCMV could play important pathological
roles in the clinical course of patients with critical illness by
lung injury,20 enhanced responsiveness of antigen-presenting
cells21 and increased activity of T cells and NK cells.22–24
However, the mechanism by which HCMV reactivation is
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associated with increased morbidity and mortality in patients
with sepsis or other critical illness is unknown. To address this
issue, T-cell immunity needs to be examined in critically ill
patients with or without HCMV reactivation.
In immunocompromised patients, T-cell immunity is crucial
for the control of HCMV.25,26 However, the role of T-cell
immunity in the control of HCMV among critically ill patients
without predisposing immunocompromised conditions has not
been clearly elucidated. In septic shock patients with HCMV
reactivation, the HCMV-speciﬁc CD4+ T-cell response has
been shown to be maintained or somewhat increased.23 Other
studies have also shown that the HCMV-speciﬁc T-cell
response is preserved despite HCMV reactivation in critically ill
patients,22 although the absence of initial T-cell immunity
against HCMV seemed to be correlated with later HCMV
reactivation.27,28 However, these studies examined HCMV-
speciﬁc T-cell responses by simply measuring IFN-γ produc-
tion without studying additional details.
In the present study, we investigated whether the HCMV-
speciﬁc T-cell response was impaired in severe sepsis patients
with HCMV reactivation. We addressed this question by
analyzing the function (particularly the polyfunctionality) of
HCMV-speciﬁc T cells in newly diagnosed severe sepsis
patients with HCMV reactivation. We found that PD-1
expression and reduced polyfunctionality of CD8+ T cells were
associated with HCMV reactivation in severe sepsis patients
without known predisposing immunocompromised factors.
MATERIALS AND METHODS
Study subjects and deﬁnitions
Severe sepsis was deﬁned as sepsis with at least one organ
dysfunction using the diagnostic criteria of the 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Deﬁnition Conference:
arterial hypoxemia, acute oliguria, creatinine increase, coagulation
abnormalities, ileus, thrombocytopenia and hyperbilirubinemia.29
We prospectively enrolled forty-eight participants with positive
HCMV IgG results, as determined by a quantitative enzyme-linked
ﬂuorescent assay (BioMérieux VIDAS, Lyon, France), among
newly diagnosed severe sepsis patients arriving at the emergency
department (ED) of Severance Hospital (Seoul, Korea) from
January 2013 to June 2014. Patients with the following circum-
stances were not eligible for this study and were excluded from
ﬁnal enrollment: use of antiviral agents to treat HCMV within the
last 3 months, known or suspected history of immune-
dysregulating disease, use of systemic immune-modulating medi-
cations such as prednisone, cyclosporine, sirolimus and tacrolimus,
and recent history of any critical illness other than severe sepsis
such as trauma, major surgery or intensive care unit (ICU)
admission within 3 months. The plasma HCMV viremia was
assessed by quantitative real-time polymerase chain reaction
(CMV Real-Time PCR kit, Biocore, Seoul, Korea; one copy/ml in
this CMV real-time PCR kit can be converted to 0.98 IU ml− 1)
from a blood sample obtained within 3 days after ED arrival. We
deﬁned HCMV reactivation in severe sepsis patients with HCMV
seropositivity as HCMV DNAemia of more than 500 copies per ml
of plasma.30 Clinical information was collected through a pro-
spective review of electronic medical records until death or
discharge. In addition, we assessed the Sequential Organ Failure
Assessment score (SOFA score) and Charlson comorbidity index of
the measured plasma HCMV level as previously described.31–33
This study was carried out in accordance with the ethical guide-
lines of the Declaration of Helsinki and was approved by Severance
Hospital, and written informed consent was obtained from all of
the participants.
Collection of peripheral blood mononuclear cells
Whole blood was obtained in EDTA tubes within 3 days after ED
arrival. Peripheral blood mononuclear cells (PBMCs) were isolated by
density gradient centrifugation using lymphocyte separation medium
(Corning, Manassas, VA, USA) and cryopreserved in liquid nitrogen
until use. Analyses of PBMCs and HCMV DNA titers were performed
with samples acquired on the same day.
Intracellular cytokine staining
Thawed PBMCs were incubated overnight in complete RPMI 1640
medium (WelGENE, Daegu, Korea). The next morning, the cells were
stimulated with a mix of CMV pp65 overlapping peptides (PepTivator
CMV pp65, Miltenyi Biotec, Auburn, CA, USA) in the presence of
anti-CD107a-PE (H4A3, BD Biosciences, San Jose, CA, USA) for 6 h.
Brefeldin A and monensin were added 1 h after stimulation. Then, the
cells were stained with Live/Dead Fixable Red Stain dye (Life
Technologies, Gaithersburg, MD, USA) and ﬂuorochrome-
conjugated monoclonal antibodies for cell surface proteins. The
stained cells were ﬁxed and permeabilized using a ﬁxation/permeabi-
lization buffer kit and stained for intracellular cytokines. The
antibodies used are as follows: anti-CD3-V500 (UCHT1, BD Bios-
ciences), anti-CD8-APC-H7 (SK1, BD Biosciences), anti-CD4-V450
(RPA-T4, BD Biosciences), anti-IFN-γ-APC (B27, BD Biosciences),
anti-TNF-α-PE-Cy7 (MAb11, eBioscience, San Diego, CA, USA), and
anti-MIP-1β-PerCP-Cy5.5 (D21–1351, BD Biosciences). The stained
cells were analyzed with an LSR II instrument (BD Biosciences) and
FlowJo v10.7 software (FlowJo, Ashland, OR, USA) according to the
gating strategy in Supplementary Figure 1. The percentage of cytokine+
cells in the unstimulated tubes was subtracted from the percentage in
the peptide mix-stimulated tubes to obtain the percentage of CMV-
speciﬁc cytokine-producing cells. T-cell polyfunctionality was analyzed
with SPICE v5.35 software (courtesy of Mario Roederer and Joshua
Nozzi, NIAID, NIH).
Immunophenotype analysis
Cryopreserved PBMCs were thawed and incubated with FcR Blocking
Reagent (Miltenyi Biotec). The FcR-blocked PBMCs were stained with
Live/Dead Fixable Red Stain dye and ﬂuorochrome-conjugated
monoclonal antibodies for cell surface proteins. The antibodies used
are as follows: anti-CD3-V500, anti-CD8-APC-H7, anti-CD14-PE-
eFluor610 (61D3, eBioscience), anti-CD19-PE-eFluor610 (HIB19,
eBioscience) and anti-PD-1-PerCP-Cy5.5 (EH12.2H7, Biolegend, San
Diego, CA, USA). The stained cells were analyzed with an LSR II
instrument and FlowJo v10.7 software according to the gating strategy
in Supplementary Figure 2.
Statistical analysis
Differences between two groups were analyzed by a nonparametric
t-test (Mann–Whitney U-test) and Fisher’s exact test. Association
between two parameters was tested by Pearson’s correlation. The
statistical analysis was performed using the software program SPSS
version 20.0 (SPSS, Chicago, IL, USA). To determine the differ-
ences in the pie charts, permutation tests in the SPICE software
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were used (10,000 permutations). Two-sided P-values were deter-
mined in all analyses, and a P-value o0.05 was considered
signiﬁcant.
RESULTS
Clinical characteristics of the study population
Among the 48 enrolled patients with severe sepsis, 19 (39.6%)
patients exhibited HCMV reactivation. The demographic and
clinical characteristics of all participants are summarized in
Table 1. In both groups, with or without HCMV reactivation,
the major infection sites of severe sepsis were the lungs and
urinary tract, and most of the causative organisms were
bacteria. We assessed the Charlson comorbidity index, which
weights the comorbid conditions in patients, and the SOFA
score, which estimates the degree of organ dysfunction,
although no signiﬁcant difference was found between the two
groups. However, the group with HCMV reactivation had a
signiﬁcantly higher frequency of mechanical ventilation use and
longer lengths of stay in the hospital and ICU than the group
without HCMV reactivation. The count of each leukocyte
subset in the peripheral blood was not different between the
two groups (data not shown).
The relative frequency of single cytokine-producing T cells
did not differ between the groups
First, we examined the functions of the HCMV-speciﬁc CD8+
and CD4+ T cells by intracellular cytokine staining for IFN-γ,
TNF-α and MIP-1β using ﬂow cytometry. For the intracellular
cytokine staining, PBMCs were stimulated with HCMV pp65
overlapping peptides. Fluorochrome-conjugated anti-CD107a
was also added to the culture to assess antigen-speciﬁc
degranulating activity of cytotoxic T cells.34 When we analyzed
the data by each function individually, there were no differ-
ences in the percentage of IFN-γ-, TNF-α- or MIP-1β-
producing CD8+ T cells or CD107a+-degranulating CD8+
T cells between the groups (Figure 1a). There were also no
differences in the percentage of IFN-γ-, TNF-α- or MIP-1β-
producing CD4+ T cells between the groups (Figure 1b).
Finally, there were no differences between the groups when
we analyzed the percentage (Figure 1c) or the absolute counts
(Figure 1d) of CD8+ or CD4+ T cells with any type of function
(total responding cells).
Polyfunctionality of CD8+ T cells was impaired in patients
with HCMV reactivation
We also analyzed the intracellular cytokine staining data based
on the number of T-cell functions. In CD8+ T cells, the
percentage of quadruple-positive cells among the total respond-
ing cells was signiﬁcantly decreased in patients with HCMV
reactivation (Figure 2a and b). In the detailed analysis of
polyfunctionality, the percentages of both quadruple-positive
(IFN-γ+, TNF-α+, MIP-1β+ and CD107a+) and triple-positive
(IFN-γ+, TNF-α+, MIP-1β+ and CD107a−) cells were signiﬁ-
cantly decreased in patients with HCMV reactivation
(Figure 2c). As presented in Figure 2d showing representative
polychromatic dot plots, the CD8+ T-cell population in
patients with HCMV reactivation exhibited a low frequency
of polyfunctional cells as well as reduced ﬂuorescence intensity
for IFN-γ and TNF-α compared to the population in patients
without HCMV reactivation. In particular, reduced ﬂuores-
cence intensity of IFN-γ or TNF-α was observed in mono-
functional (single-positive) cells compared to polyfunctional
(quadruple-positive or triple-positive) cells (Figure 2d). In
contrast, polyfunctionality and ﬂuorescence intensity were
well-maintained in the CD8+ T-cell population in patients
without HCMV reactivation (Figure 2d). In the CD4+ T cells,
the percentage of polyfunctional (3 functions or ⩾ 2 functions)
cells among the total responding cells did not differ between
the groups (Figure 2e and f). A detailed analysis of the
polyfunctionality with every possible combination of functions
also showed no difference between the groups (Figure 2g).
Polyfunctionality of T cells was also analyzed by absolute
counts of responding T cells (Supplementary Figure 3), and the
data showed a similar tendency with those based on the
percentage.
These ﬁndings led us to analyze the intracellular cytokine
staining data by geometric mean ﬂuorescence intensity (gMFI).
When we analyzed the data for each single function by gMFI,
we found that the gMFI values of TNF-α and CD107a were
Table 1 Demographic and clinical characteristics of the
enrolled severe sepsis patients
HCMV reactivation
Characteristics Yes (n=19) No (n=29) P-value
Age, year 71.5 (49–95) 70 (21–89) 0.540a
Sex, male 13 (68.4) 16 (55.2) 0.364b
HCMV DNA titer (copies per ml) 1830 (555–45×106) o500
Infection site
Lung 11 (57.9) 10 (34.5) 0.130b
Urinary tract 3 (15.8) 7 (24.1) 0.719b
Abdomen 3 (15.8) 6 (20.7) 1.000b
Others 1 (5.3) 6 (20.7) 0.225b
Causative organism
Bacteria 15 (83.2) 28 (96.6) 0.150b
Fungus 1 (5.6) 1 (3.4) 1.000b
Virus 1 (5.6) 0 (0.0) 0.383b
Mixed 1 (5.6) 0 (0.0) 0.383b
Charlson comorbidity index 1.5 (0–8) 1 (0–4) 0.078a
SOFA score 7.5 (0–18) 5 (0–16) 0.355a
Clinical outcomes
Mechanical ventilationc 8 (42.1) 3 (10.3) 0.020a
Total admission duration, day 21 (6–133) 14 (1–75) 0.031a
ICU care 9 (47.4) 7 (24.1) 0.072a
Duration of ICU care, day 3 (0–75) 0 (0–12) 0.023a
In-hospital all-cause mortality 9 (47.4) 6 (20.7) 0.064a
Abbreviations: HCMV, human cytomegalovirus; ICU, intensive care unit; SOFA
score, Sequential Organ Failure Assessment score.
The data were expressed as median (range) and number (percent).
aMann–Whitney U-test.
bFisher’s exact test.
cThe number of patients who had ever received the mechanical ventilation during
hospitalization.
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signiﬁcantly reduced in the CD8+ T-cell population in patients
with HCMV reactivation (Figure 3a). However, the difference
was not observed in the CD4+ T-cell population between the
groups (Figure 3b).
PD-1 expression in the CD8+ T-cell population was
increased in patients with severe sepsis with HCMV
reactivation
Next, we performed immunophenotype analysis to examine
the expression of a T-cell exhaustion marker, programmed cell
death protein 1 (PD-1), in the CD8+ T-cell population. In the
CD8+ T-cell population, PD-1 expression was signiﬁcantly
increased in patients with HCMV reactivation in terms of both
the percentage of PD-1+ cells and gMFI of PD-1 (Figure 4a).
These ﬁndings suggested that CD8+ T cells are exhausted in
severe sepsis patients with HCMV reactivation. We also
analyzed the correlation between PD-1 expression and CD8+
T-cell polyfunctionality and found that the percentage of
PD-1+ cells in the CD8+ T-cell population was inversely
correlated with the percentage of polyfunctional (quadruple-
positive) cells among the total responding CD8+ T cells
(Figure 4b). Moreover, the percentage of cells expressing
PD-1 in the CD8+ T-cell population was positively correlated
with HCMV DNA titers (Figure 4c).
Taken together, these ﬁndings demonstrate that the CD8+
T-cell population in patients with HCMV reactivation has a
comparable percentage of cytokine-producing cells but reduced
polyfunctionality compared to the CD8+ T-cell population in
patients without HCMV reactivation. Furthermore, reduced
polyfunctionality is associated with PD-1 expression in CD8+
T cells in patients with severe sepsis.
DISCUSSION
As the ﬁrst report of HCMV reactivation in non-
immunocompromised critically ill patients was published,6
it has become widely accepted that HCMV reactivation is
correlated with increased morbidity and mortality in criti-
cally ill patients.7–14 However, the immunological character-
istics of critically ill patients with HCMV reactivation have
not been clearly elucidated. In the present study, we enrolled
Figure 1 The relative frequency of single cytokine-producing T cells in severe sepsis patients. Peripheral blood mononuclear cells (PBMCs)
from severe sepsis patients without (n=27) and with (n=13) human cytomegalovirus (HCMV) reactivation were stimulated with HCMV
pp65 overlapping peptides, and intracellular cytokine staining for IFN-γ, TNF-α and MIP-1β was performed. Fluorochrome-conjugated anti-
CD107a was also added to the culture when the PBMCs were stimulated to assess the antigen-speciﬁc degranulating activity of the
T cells. The data were analyzed for single cytokine+ cells or CD107a+ cells in the total CD8+ T-cell population (a) and for single cytokine+
cells in the total CD4+ T-cell population (b). The data were also analyzed for the percentage of the total CD8+ or CD4+ T-cell population
(c) or the absolute counts (d) of T cells with any type of function (total responding cells). The horizontal lines represent the median values.
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severe sepsis patients with or without HCMV reactivation
and examined T-cell responses in detail using intracellular
cytokine staining and polyfunctionality analysis. We found
that the polyfunctionality of HCMV-speciﬁc CD8+ T cells
was impaired in patients with HCMV reactivation and that
PD-1 expression in the CD8+ T cells was increased in
patients with HCMV reactivation, suggesting the occurrence
of sepsis-induced T-cell immunosuppression.35 In addition,
the relative frequency of the polyfunctional CD8+ T cells was
inversely correlated with the relative frequency of PD-1+
cells in the CD8+ T-cell population. This result is consistent
with a previous ﬁnding that the polyfunctionality of CD8+
Figure 2 Polyfunctionality of human cytomegalovirus (HCMV) pp65-speciﬁc T cells in severe sepsis patients. The data from Figure 1 were
analyzed for the polyfunctionality of T cells according to the number of T-cell functions. CD8+ T cells were analyzed for IFN-γ, TNF-α,
MIP-1β and CD107a (a–d), and CD4+ T cells were analyzed for IFN-γ, TNF-α and MIP-1β (e–g). The pie graphs show the fraction of
T cells positive for a given number of functions among T cells with any type of function (total responding cells) (a, e). The percentage of
T cells positive for a given number of functions was compared between severe sepsis patients without (n=27) and with (n=13) CMV
reactivation (b, f). Detailed analyses of polyfunctionality were presented with every possible combination of functions, and the data were
compared between the groups (c, g). Representative polychromatic dot plots for IFN-γ and TNF-α are shown. T cells positive for a given
number of functions are marked by different colors to show their distribution in the dot plots for IFN-γ and TNF-α (d). The horizontal lines
represent the median values. *Po0.05, **Po0.01.
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T cells against HIV is inversely correlated with the expres-
sion of PD-1, CD160 and 2B4 in HIV-infected patients.36
Moreover, the percentage of PD-1-expressing cells in the
CD8+ T-cell population is positively correlated with HCMV
DNA titers.
In the case of immunocompromised patients, PD-1 eleva-
tion has been reported to correlate with HCMV
reactivation.37–39 We found that PD-1 expression was increased
in sepsis patients with HCMV reactivation in the present study,
and these data are consistent with previous ﬁndings that PD-1
expression is increased in severe sepsis.35 Based on our current
ﬁndings and previous ﬁndings, it is plausible that severe sepsis
may cause clinically relevant immunosuppression and that the
sepsis-induced immunosuppression represented by PD-1 upre-
gulation results in HCMV reactivation. In addition, we suggest
that HCMV reactivation could be a surrogate marker for severe
immunosuppression among sepsis patients. However, the
clinical relevance of HCMV reactivation needs to be further
investigated in the context of the management of severe sepsis
patients.
In the intracellular cytokine staining experiments, the percen-
tage of each subset of single cytokine+ cells among the CD8+ or
CD4+ T-cell population did not differ between patients with or
without HCMV reactivation. These data are in accordance with
previous ﬁndings,22,23,27 which showed that IFN-γ-producing
HCMV-speciﬁc T cells are maintained in septic and critically ill
Figure 3 Geometric mean ﬂuorescence intensity (gMFI) of cytokine-producing T cells in severe sepsis patients. The data from Figure 1
were analyzed for the gMFI of each function. The gMFI of the cytokine-producing cell population was divided by the gMFI of the cytokine-
negative cell population to normalize the data. The data were analyzed for single cytokine+ cells or CD107a+ cells in the CD8+ T cells (a)
and for single cytokine+ cells in the CD4+ T cells (b). The horizontal lines represent the median values. *Po0.05.
Figure 4 Correlation between PD-1 expression and the polyfunctionality of CD8+ T cells in severe sepsis patients. (a) The percentage of
PD-1+ cells and gMFI of PD-1 in the CD8+ T-cell population were compared between severe sepsis patients without (n=13) and with
human cytomegalovirus (HCMV) reactivation (n=6). (b) Correlational analysis was performed between the percentage of PD-1+ cells in the
total CD8+ T-cell population and the percentage of highly polyfunctional (quadruple-positive) cells among the CD8+ T cells with any type of
function (total responding CD8+ T cells). (c) Correlational analysis was performed between the percentage of PD-1+ cells in the total CD8+
T-cell population and HCMV DNA titers. The horizontal lines represent the median values. *Po0.05, **Po0.01.
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patients with HCMV reactivation. However, in our current
study, CD8+ T-cell polyfunctionality was signiﬁcantly reduced in
patients with HCMV reactivation, and the gMFIs of TNF-α and
CD107a in CD8+ T cells was signiﬁcantly decreased in patients
with HCMV reactivation. A previous study using mouse models
reported that septic stimuli induce a transient contraction of
murine cytomegalovirus (MCMV)-speciﬁc CD8+ T cells and
MCMV reactivation.19 In this previous study, the number of
MCMV-speciﬁc CD8+ T cells was decreased upon lipopolysac-
charide administration. However, the percentage of single
cytokine-positive T cells was maintained even with HCMV
reactivation in our study, while CD8+ T cell polyfunctionality
was reduced in the case of HCMV reactivation.
Interestingly, there is a sequential order to the loss of T-cell
functions caused by T-cell exhaustion. First, exhausted T cells
lose the ability to produce IL-2 and induce cytotoxicity; then,
the production capacities of TNF-α, IFN-γ and MIP-1β are
progressively lost as T-cell exhaustion becomes more severe.40
In our data, the gMFIs of TNF-α and CD107a (a marker of
degranulating cytotoxic activity) were decreased in patients
with HCMV reactivation, while the gMFIs of IFN-γ and
MIP-1β were preserved, suggesting that the HCMV-speciﬁc
CD8+ T cells were in the early stage of T-cell exhaustion in the
severe sepsis patients with HCMV reactivation.
PD-1 is a T cell inhibitory receptor and is considered a
marker of T-cell exhaustion.40 PD-1 is upregulated in T cells
after prolonged antigenic stimulation in the context of cancer
and chronic viral infection and is responsible for T-cell
exhaustion in these diseases.41,42 Therefore, anti-PD-1 or anti-
PD-L1 blocking antibodies have been used for cancer
treatment.41,42 Recently, PD-1 upregulation has been reported
to correlate with poor outcomes in sepsis,43,44 and the blockade
of the PD-1 pathway is now considered to be an immunomo-
dulatory therapy in sepsis-induced immunosuppression.45,46
Therefore, it is of interest to determine whether PD-1/PD-L1
blocking therapy can reduce the reactivation of HCMV in
patients with severe sepsis. Furthermore, an investigation into
whether PD-1/PD-L1 blocking therapy can be guided by HCMV
reactivation (which represents severe immunosuppression
among sepsis patients) is necessary in patients with severe sepsis.
One of the shortcomings of the current study is the study
time point. We analyzed HCMV reactivation and T-cell
functions within 3 days after the patients arrived at the ED.
However, T-cell functions can change over time, and HCMV
can reactivate at a later time point during sepsis.9,19,23 There-
fore, sepsis patients who suffered HCMV reactivation at a later
time point might have been excluded from the HCMV
reactivation group in the present study. Moreover, the stimula-
tion of CD8+ T cells using HCMV pp65 overlapping peptide
mix is not enough to measure the whole CD8+ T-cell responses
against HCMV antigens because there are HCMV pp65 non-
responders among HCMV-infected patients.47 Further studies
with HCMV antigens other than pp65 are warranted. Further
investigations with serial samples at later time points would be
also required to address HCMV-speciﬁc T-cell functions in
severe sepsis patients more clearly. In addition, it is hard to
know whether the decreased CD8+ T-cell polyfunctionality is a
cause or consequence of HCMV reactivation in this study. This
question should be addressed by future studies examining
proliferation markers such as Ki-67 in HCMV-speciﬁc T cells.
In conclusion, we demonstrate that HCMV reactivation in
severe sepsis patients is associated with decreased polyfunction-
ality and increased PD-1 expression of CD8+ T cells and that
HCMV reactivation can be a surrogate marker for severe
immunosuppression among sepsis patients.
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